Cardiff Oncology, Inc. (CRDF)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.76-13.07%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · CRDF
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||||||
| Revenues | 0.5 | 0.6 | 0.7 | 0.5 | 0.4 | 0.4 | 0.4 | 0.2 | 0.4 | 0.5 | 0.4 | 0.3 | 0.3 | 0.3 | 0.5 |
| Total Revenues | — | — | — | — | — | — | 0.4 | 0.2 | 0.4 | 0.5 | 0.4 | 0.3 | 0.3 | 0.3 | 0.5 |
| Cost of Revenues | — | — | — | — | — | — | — | 0.0 | 0.6 | 1.8 | 1.7 | 0.6 | 0.0 | — | — |
| Operating Expenses & Income | |||||||||||||||
| Selling, General & Admin | 16.8 | 14.2 | 12.5 | 13.0 | 13.2 | 11.8 | 8.2 | 5.8 | 8.0 | — | — | — | — | 7.0 | — |
| R&D Expenses | — | — | — | — | 27.1 | 17.4 | 11.2 | — | — | — | — | — | — | — | — |
| Other Operating Expenses, Total | — | — | — | — | — | — | (0.0) | 0.0 | (0.2) | (0.2) | (0.1) | (0.0) | — | — | — |
| Operating Income | (42.3) | (49.0) | (48.7) | (45.4) | (39.9) | (28.9) | (19.1) | (16.7) | (17.1) | (25.6) | (40.1) | (25.3) | (14.9) | (10.7) | (4.8) |
| Earnings from Continuing Operations | |||||||||||||||
| Interest Expense | — | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 1.0 | — | 1.5 | 0.8 | 0.0 | 0.1 |
| Interest & Investment Income | 2.2 | 3.1 | 3.3 | 4.1 | 1.6 | 0.3 | 0.1 | 0.2 | 0.2 | 0.1 | — | — | — | — | — |
| Net Interest Expenses | — | — | — | — | — | (0.3) | (0.1) | (0.2) | (0.2) | 0.9 | — | — | — | — | — |
| Other Non-Operating Income / Expenses | 2.2 | 3.1 | 3.2 | 4.0 | 1.2 | 0.6 | (0.2) | — | — | — | — | — | — | — | — |
| EBT, Incl. Unusual Items | — | (45.9) | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — |
| Net Income | |||||||||||||||
| Net Income | 5.8 | (45.9) | (45.4) | (0.0) | (38.7) | (28.3) | (19.3) | (16.4) | (16.5) | (24.9) | (39.2) | (27.5) | (14.3) | (11.8) | (11.6) |
| Per Share | |||||||||||||||
| Basic EPS | 0.08 | (0.69) | (0.95) | (0.93) | (0.89) | (0.73) | (1.08) | — | (8.26) | (51.76) | (1.30) | (1.05) | (0.76) | — | — |
| Diluted EPS | 0.08 | (0.69) | (0.95) | (0.93) | (0.89) | (0.73) | (1.08) | — | (8.26) | (51.76) | (1.37) | (1.21) | (0.88) | — | — |
| Revenue per Share | 0.01 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 68.4 | 66.8 | 47.7 | 44.7 | 43.6 | 39.0 | 20.9 | 6.0 | 2.3 | 0.5 | 30.2 | 26.2 | 18.9 | — | — |
| Diluted Weighted Avg Shares | 68.4 | 66.8 | 47.7 | 44.7 | 43.6 | 39.0 | 20.9 | — | 2.3 | 0.5 | 30.3 | 26.5 | 19.1 | — | — |
| Supplemental | |||||||||||||||
| EBITDA | — | (48.6) | (48.2) | (45.0) | (39.7) | (28.4) | (18.6) | (16.2) | (16.2) | (24.3) | (39.1) | (24.9) | (14.7) | (10.6) | (4.8) |
| EBIT | (42.3) | (49.0) | (48.7) | (45.4) | (39.9) | (28.9) | (19.1) | (16.7) | (17.1) | (25.6) | (40.1) | (25.3) | (14.9) | (10.7) | (4.8) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.